Alembic Pharmaceuticals — 360° view

Alembic Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹2,603 crore and net profit of ₹334 crore for the September 2026 quarter.

Alembic Pharmaceuticals (NSE: APLLTD) closed at ₹1,040.95 on 20 Nov 2026, up 15.7% over the past year. Its market capitalisation is ₹20,461 crore and it trades at 22.8 times earnings.

Share price
₹1,040.95 (20 Nov 2026)
Market cap
₹20,461 Cr (20 Nov 2026)
P/E
22.82 (20 Nov 2026)
Revenue
₹2,603 Cr (September 2026 quarter)
Net profit
₹334 Cr (September 2026 quarter)
ROCE
12.6% (FY26)
ROE
13.4% (FY26)
Book value
₹302 (FY26)
Dividend yield
1.15% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,075.00 / ₹635.80 (20 Nov 2026)
1-year return
15.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: APLLTD

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.